Navigation Links
Antibiotic treats lymphoma of the eye

The common antibiotic doxycycline effectively treats a type of lymphoma associated with chlamydia infection, according to a study in the October 4 issue of the Journal of the National Cancer Institute.

Ocular adnexal lymphoma of the MALT-type (OAL) is a kind of cancer of the eyelids and related tissues. It is not often fatal, but its symptoms can compromise a patient's quality of life. Some research has suggested an association between OAL and infection with the bacteria Chlamydia psittaci.

Andres J. M. Ferreri, M.D., of the San Raffaele H Scientific Institute in Milan, Italy, and colleagues examined whether doxycycline was an effective treatment for OAL. They gave 27 OAL patients a 3-week course of doxycycline therapy, whether they were positive or negative for chlamydia. They looked for tumor progression every 6 months.

The authors found that doxycycline treatment caused lymphoma to regress in both patients who did not test positive for the disease and those who did. They suggest that doxycycline may be a useful therapy even in patients where other treatments have failed, and it is a valid alternative to chemotherapy and radiation without causing the same toxic side-effects. Patients treated with doxycycline had a 66% rate of disease-free survival.

"Our prospective trial revealed that doxycycline is a fast, safe, and active treatment for OAL, both at initial diagnosis and at relapse," the authors write.

In an accompanying editorial, Emanuel Zucca, M.D., and Francesco Bertoni, M.D., of the Oncology Institute of Southern Switzerland, write, "While doxycycline appears to be an easy-to-implement therapeutic approach, we strongly encourage all physicians to enroll patients in clinical prospective trials to help answer these questions."


'"/>

Source:Journal of the National Cancer Institute


Page: 1

Related biology news :

1. Antibiotic Resistant Bacterium Uses Sonar-like Strategy to “See?Enemies or Prey
2. Antibiotic might fight HIV-induced neurological problems
3. New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal
4. To Stop Evolution: New Way Of Fighting Antibiotic Resistance Demonstrated By Scripps Scientists
5. Chemical Engineer Kao Explores Antibiotic Synthesis With DNA Chips
6. Use of Antibiotics for Acne May Increase Risk of Common Illness
7. Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance
8. Antibiotic inhibits cancer gene activity
9. Antarctic ice shelf retreats happened before
10. Stem cell therapy successfully treats heart attack in animals
11. Gene therapy advance treats hemophilia in mouse models
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology: